Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma

Glioblastoma is characterized by an aggressive and aberrant vascular network that promotes tumor progression and hinders effective treatment; the median survival is 16 mo despite standard-of-care therapies. There is a need to improve therapeutic options for this disease. We hypothesized that antibod...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Nucl Med
Egile Nagusiak: Behling, Katja, Maguire, William F., López Puebla, José Carlos, Sprinkle, Shanna R., Ruggiero, Alessandro, O'Donoghue, Joseph, Gutin, Philip H., Scheinberg, David A., McDevitt, Michael R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Society of Nuclear Medicine 2016
Gaiak:
Basic Science Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5050148/
https://ncbi.nlm.nih.gov/pubmed/27127217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.115.171371
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak